Evaluation of BAFF, APRIL and CD40L in Ocrelizumab-Treated pwMS and Infectious Risk
Sign Up to like & getrecommendations! Published in 2023 at "Biology"
DOI: 10.3390/biology12040587
Abstract: Simple Summary Since B cells have been linked to multiple sclerosis (MS) and its progression as well as T cells, the second-generation anti-CD20 recombinant humanized monoclonal antibody ocrelizumab has been approved for MS treatment. Although… read more here.
Keywords: cd40l; infectious risk; april cd40l; plasma baff ... See more keywords